Influenza and mortality for non-small cell lung cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13114-e13114
Author(s):  
Connor J Kinslow ◽  
Yuankun Wang ◽  
Yi Liu ◽  
Konstantin M. Zuev ◽  
Tony J. C. Wang ◽  
...  

e13114 Background: Lung cancer is the leading cause of cancer deaths in the United States and worldwide. While influenza illness is known to be particularly dangerous for frail and elderly patients, the relationship between influenza illness and outcomes in cancer patients remains largely unknown. Methods: Monthly mortality rates for all patients at risk, as well as newly diagnosed patients, with non-small cell lung cancer (NSCLC) diagnosed between 2009 and 2015 were compared during high and low flu months using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the Center for Disease Control and Prevention (CDC) website. Influenza severity was determined by the percentage of outpatient visits to healthcare providers for influenza-like illness (ILI). CDC ILI activity levels were matched with SEER data by month and state. State-months with an ILI activity level of 8 or higher were considered to be high flu months, as defined by the CDC. Results: 195,038 patients with NSCLC from 13 states were included in the analysis. 52 out of 1,081 state-months (5.1%) had high flu activity. Monthly mortality rates for low and high flu months were 4.9 and 5.7%, respectively (p = .001). The monthly mortality rate for newly diagnosed patients was also significantly higher during high flu months (9.4 vs. 10.2%, p = .01). When the analysis was limited to winter months only, monthly mortality rates for low and high flu months were 4.7 and 5.3%, respectively (p = .02). The relationship between flu severity and mortality was also observed at the individual state level. Conclusions: Increased influenza severity is associated with higher mortality rates for NSCLC patients. Future research should elucidate the relationship between vaccination and survival in lung cancer patients.

1994 ◽  
Vol 12 (6) ◽  
pp. 1126-1129 ◽  
Author(s):  
C L Loprinzi ◽  
R M Goldberg ◽  
J Q Su ◽  
J A Mailliard ◽  
S A Kuross ◽  
...  

PURPOSE Hydrazine sulfate, an agent that appears to inhibit gluconeogenesis, has been studied in cancer patients for approximately 20 years. There was a recent resurgence of interest in this drug when subset analysis of a small placebo-controlled, double-blind, clinical trial reported improved survival among non-small-cell lung cancer patients with a good performance status who were randomized to receive this drug along with standard chemotherapy. PATIENTS AND METHODS Patients on this trial had newly diagnosed, unresectable non-small-cell lung cancer and were treated with cisplatin and etoposide. In addition, they were randomized to receive hydrazine sulfate or placebo in a double-blind manner. RESULTS A total of 243 patients were randomized. Response rates were similar in the two treatment arms. There were trends for worse time to progression and survival in the hydrazine sulfate arm. No significant differences were noted in the two study arms with regard to toxicity or quality of life (QL). CONCLUSION This trial failed to demonstrate any benefit for patients who received hydrazine sulfate.


2021 ◽  
pp. 100127
Author(s):  
Shona Pedersen ◽  
Joachim Bavnhøj Hansen ◽  
Raluca Georgiana Maltesen ◽  
Weronika Maria Szejniuk ◽  
Trygve Andreassen ◽  
...  

Oncology ◽  
2020 ◽  
Vol 98 (7) ◽  
pp. 460-467
Author(s):  
Hironori Yoshida ◽  
Young Hak Kim ◽  
Shigeaki Iwatsubo ◽  
Chikara Sakaguchi ◽  
Yuichi Sakamori ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document